- Home
- ZLAB vs NVCR Comparison
ZLAB vs NVCR Comparison
Compare ZLAB & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- NVCR
- Stock Information
- Founded
- ZLAB 2013
- NVCR 2000
- Country
- ZLAB China
- NVCR Switzerland
- Employees
- ZLAB N/A
- NVCR N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- NVCR Medical/Dental Instruments
- Sector
- ZLAB Health Care
- NVCR Health Care
- Exchange
- ZLAB Nasdaq
- NVCR Nasdaq
- Market Cap
- ZLAB 3.6B
- NVCR 1.9B
- IPO Year
- ZLAB 2017
- NVCR 2015
- Fundamental
- Price
- ZLAB $32.54
- NVCR $17.60
- Analyst Decision
- ZLAB Buy
- NVCR Buy
- Analyst Count
- ZLAB 5
- NVCR 7
- Target Price
- ZLAB $54.28
- NVCR $32.43
- AVG Volume (30 Days)
- ZLAB 781.8K
- NVCR 1.4M
- Earning Date
- ZLAB 08-05-2025
- NVCR 07-24-2025
- Dividend Yield
- ZLAB N/A
- NVCR N/A
- EPS Growth
- ZLAB N/A
- NVCR N/A
- EPS
- ZLAB N/A
- NVCR N/A
- Revenue
- ZLAB $418,326,000.00
- NVCR $621,711,000.00
- Revenue This Year
- ZLAB $44.07
- NVCR $5.56
- Revenue Next Year
- ZLAB $49.13
- NVCR $9.19
- P/E Ratio
- ZLAB N/A
- NVCR N/A
- Revenue Growth
- ZLAB 43.72
- NVCR 18.27
- 52 Week Low
- ZLAB $16.01
- NVCR $14.17
- 52 Week High
- ZLAB $44.34
- NVCR $34.13
- Technical
- Relative Strength Index (RSI)
- ZLAB 40.19
- NVCR 49.74
- Support Level
- ZLAB $34.26
- NVCR $16.81
- Resistance Level
- ZLAB $35.72
- NVCR $18.59
- Average True Range (ATR)
- ZLAB 1.12
- NVCR 0.74
- MACD
- ZLAB -0.54
- NVCR 0.08
- Stochastic Oscillator
- ZLAB 3.83
- NVCR 56.18
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.